Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14466906 | 0.94 | FAAH (0.57) | EPHX2FAAHCNR1DNM1LPAR1 | |
| SCHEMBL29310916 | 0.94 | FAAH (0.57) | EPHX2FAAHCNR1DNM1LPAR1 | |
| SCHEMBL25516067 | 0.94 | FAAH (0.57) | EPHX2FAAHCNR1DNM1LPAR1 | |
| SCHEMBL23365838 | 0.94 | FAAH (0.57) | EPHX2FAAHCNR1DNM1LPAR1 | |
| SCHEMBL24759152 | 0.92 | FAAH (0.59) | EPHX2FAAHCNR1DNM1LPAR1 | |
| SCHEMBL30180923 | 0.92 | EPHX2 (0.50) | EPHX2FAAHSMN1; SMN2DNM1LPAR1 | |
| SCHEMBL16355251 | 0.90 | SMN1; SMN2 (0.47) | EPHX2FAAHCNR1SMN1; SMN2CASP2 | |
| SCHEMBL14438830 | 0.90 | FAAH (0.61) | EPHX2FAAHCNR1CNR2DNM1 | |
| SCHEMBL26706549 | 0.90 | SMN1; SMN2 (0.49) | FAAHCNR1SMN1; SMN2DNM1LPAR1 | |
| SCHEMBL14438832 | 0.90 | FAAH (0.61) | EPHX2FAAHCNR1CNR2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |